Read More

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment In Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes In Poster Presentation At WCIRDC

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt Week 26, 22 weeks after the last dose of BMF-219, participants in the 100

BMEA

Read More

Post Holdings Inc Updates Its Outlook For FY24 Adjusted EBITDA To Range Of $1.22B-$1.28B; Michael Foods’ Third-Party Contracted Egg-Laying Flocks In Iowa And Ohio Tested Positive For Avian

Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today provided information regarding avian influenza incidents at two of Michael Foods' third-party contracted egg-laying facilities. Post also

POST